# Escitalopram for Agitation in Alzheimer's Disease

> **NCT03108846** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **JHSPH Center for Clinical Trials** · enrollment: 187 (actual)

## Conditions studied

- Dementia

## Interventions

- **DRUG:** Escitalopram
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03108846
- **Lead sponsor:** JHSPH Center for Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-03
- **Primary completion:** 2024-04-05
- **Final completion:** 2025-05
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2025-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03108846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03108846, "Escitalopram for Agitation in Alzheimer's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03108846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*